Press Release
View printer-friendly version << Back
Omeros Corporation to Host Conference Call on Fourth Quarter and Full Year 2009 Results on March 31

SEATTLE, March 15 /PRNewswire-FirstCall/ --Omeros Corporation (Nasdaq:OMER - News), a biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system, today announced that it will hold a conference call on Wednesday, March 31, 2010 to discuss the Company's fourth quarter and full year 2009 results and provide a corporate update. Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros, will host the call beginning at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). A press release for the fourth quarter and full year ended December 31, 2009 will be released on March 31.

To access the live call by telephone, please dial 888-500-6973 (United States and Canada) or 719-457-2637 (International). In addition, the live conference call is being webcast and can be accessed on the "Events" page of the Company's website at http://www.omeros.com.

A replay of the webcast will be available on the Company's website for one week.  A telephone replay will also be available for one week starting at 7:30 p.m. Eastern Time on March 31, which can be accessed by dialing 888-203-1112 (United States and Canada) or 719-457-0820 (International) and entering conference ID number 2664433.

About Omeros Corporation

Omeros is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. The Company's most clinically advanced product candidates are derived from its proprietary PharmacoSurgery™ platform designed to improve clinical outcomes of patients undergoing a wide range of surgical and medical procedures. Omeros has five ongoing clinical development programs, including four from its PharmacoSurgery™ platform and one from its Addiction program, the most advanced of which is in Phase 3 clinical trials. Omeros may also have the near-term capability, through its GPCR program, to add an unprecedented number of wholly new drug targets to the market. Behind its clinical candidates and GPCR platform, Omeros is building a diverse pipeline of antibody and small-molecule preclinical programs targeting inflammation and central nervous system disorders.